Sibel Health and LookDeep Health have announced a strategic partnership combining continuous vital signs monitoring with real-time bedside AI for hospital patients. The collaboration integrates Sibel's FDA-cleared ANNE One wearable sensing platform with LookDeep's aimee clinical AI assistant, which uses visual, audio and physiologic data to provide contextual patient monitoring. The partnership aims to improve patient monitoring outside intensive care units, where most patients receive only intermittent checks. By combining continuous wearable vitals with real-time bedside context, the system helps clinicians detect early deterioration whilst reducing alarm fatigue and unnecessary interruptions. The integration is designed to work alongside existing hospital systems without vendor lock-in. Sibel Health's sensors comply with IEEE 11073 SDC standards, whilst LookDeep offers peer-reviewed AI technology. The partnership will initially launch with select health systems before wider availability.

FDA accepts Sibel Health's Aria sensor for COA qualification. Sibel Health received a $500,000 FDA grant for its scratch sensor, raising its total funding to exceed $1m. Sibel Health has received acceptance from the US Food and Drug Administration (FDA) into the clinical outcome assessment (COA) qualification programme under the drug development tool (DDT) framework for its Aria cough monitoring sensor. This development marks Sibel Health's third FDA DDT COA acceptance, advancing technology for chronic refractory cough (CRC) measurement in adults. The company previously secured DDT COA acceptances for a scratch sensor targeting atopic dermatitis and a swallow sensor designed for Parkinson's disease. Sibel Health now accounts for three of eight digital health technologies accepted by the FDA DDT COA programme as of 12 February 2026. The company recently received a $500,000 grant from the FDA to qualify its scratch sensor, increasing its total direct funding for digital endpoint development to over $1m. The Aria sensor is Sibel Health's latest wearable device. It attaches at the suprasternal notch and uses acousto-mechanical sensing for detecting and quantifying real-time cough events by capturing acoustic signatures and mechanical vibrations. GlobalData Strategic Intelligence US tariffs are shifting - will you react or anticipate? Don't let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData It operates outside of audible voice frequencies, helping address privacy concerns associated with traditional audio monitors. Coupled with an AI algorithm, the Aria sensor eliminates the need for manual cough event labelling. Sibel Health CEO and co-founder Steve Xu said: "Receiving FDA acceptance into the DDT Qualification Programme represents a major step forward in our mission to provide clinicians and researchers with reliable, patient-friendly tools for measuring chronic cough." The Aria sensor provides continuous, privacy-conscious monitoring, minimises researcher workload through automated detection, and supports 24-hour data collection with wireless charging and mobile connectivity. Sibel Health will now submit a comprehensive qualification plan as part of the next phase of FDA review. Upon successful qualification, Aria may serve as an endpoint in clinical trials for CRC treatments. Its technology may also be applied to other respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, post-infectious cough, and idiopathic pulmonary fibrosis (IPF). In March 2025, Sibel Health secured $30m in an equity financing round to expedite the commercial deployment of its Anne One monitoring platform.

Sibel Health has received FDA acceptance into the Drug Development Tool Qualification Programme for its Aria cough monitoring sensor, marking the company's third DDT Clinical Outcome Assessment acceptance. This brings Sibel's total to three out of eight digital health technologies ever accepted into the programme as of February 2026. The Aria sensor adheres to the neck and uses acousto-mechanic sensing to detect cough events in real-time without capturing identifiable speech, addressing privacy concerns. The device targets chronic refractory cough, which affects up to seven million US adults annually. Current clinical trials rely on subjective patient diaries prone to inaccuracies. The FDA identified objective cough frequency as a key outcome measure for drug development targeting adult refractory chronic cough. Sibel will now submit a Qualification Plan to advance the regulatory process.